SCH 50971
Latest Information Update: 07 Sep 2001
Price :
$50 *
At a glance
- Originator Schering-Plough
- Class Anxiolytics; Gastrokinetics
- Mechanism of Action Histamine H3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Gastrointestinal disorders; Migraine
Most Recent Events
- 07 Sep 2001 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 07 Sep 2001 No-Development-Reported for Gastrointestinal disorders in USA (Unknown route)
- 07 Sep 2001 No-Development-Reported for Migraine in USA (Unknown route)